A Supplement (hereinafter referred to as “Supplement”) to OXFORD-SSI Amended and Restated License and Supply Agreement (hereinafter re-ferred to as the “Agreement”). Background:A Supplement • October 25th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Whereas, SSI advised OXFORD that the opportunity to file a patent application directed towards the M.tuberculosis antigen TB12.3 would expire on October 1, 2010 and that SSI did not believe this antigen to be of importance within TB vac-cine production and/or TB diagnostic; and
